Jpmorgan Chase & CO Impel Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.08 - $2.75 $2,916 - $7,425	-2,700 Reduced 88.26%	359 $0
Q1 2023 May 11, 2023	BUY	$0.96 - $4.1 $2,592 - $11,069	2,700 Added 752.09%	3,059 $4,000
Q4 2022 Feb 13, 2023	SELL	$2.59 - $4.0 $2,491 - $3,848	-962 Reduced 72.82%	359 $1,000
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $1,786 - $2,879	309 Added 30.53%	1,321 $6,000
Q2 2022 Aug 11, 2022	SELL	$5.83 - $10.12 $27,418 - $47,594	-4,703 Reduced 82.29%	1,012 $9,000
Q1 2022 May 11, 2022	BUY	$5.86 - $9.85 $9,481 - $15,937	1,618 Added 39.49%	5,715 $36,000
Q4 2021 Feb 10, 2022	BUY	$8.33 - $12.14 $13,619 - $19,848	1,635 Added 66.41%	4,097 $36,000
Q3 2021 Nov 12, 2021	BUY	$8.38 - $26.13 $20,631 - $64,332	2,462 New	2,462 $30,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.